

UCSF

UC San Francisco Previously Published Works

Title

Prostate cancer with a pseudocapsule at MR imaging: a marker of high grade and stage disease?

Permalink

<https://escholarship.org/uc/item/6hx884w9>

Journal

Clinical Imaging, 40(3)

ISSN

0899-7071

Authors

Bonde, Apurva A
Korngold, Elena K
Foster, Bryan R
[et al.](#)

Publication Date

2016-05-01

DOI

10.1016/j.clinimag.2015.12.015

Peer reviewed



Published in final edited form as:

Clin Imaging. 2016 ; 40(3): 365–369. doi:10.1016/j.clinimag.2015.12.015.

Prostate cancer with a pseudocapsule at MR imaging: A marker of high grade and stage disease?

Apurva A. Bonde, MD, Elena K. Korngold, MD, Bryan R. Foster, MD, Antonio C. Westphalen, MD, David R. Pettersson, MD, Megan L. Troxell, MD PhD, Jeffry P. Simko, MD PhD, and Fergus V. Coakley, MD

Departments of Diagnostic Radiology (AAB, EKK, BRF DP, FVC), Pathology (MLT), Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Mail Code: L340, Portland, OR 97239

Departments of Radiology and Biomedical Imaging (ACW) and Anatomic Pathology (JPS), University of California San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143-0628

Abstract

Clinicopathological correlates of prostate cancer associated with a pseudocapsule at T2-weighted MR imaging are presented in a retrospective series of 15 patients. Fourteen of 15 tumors involved the peripheral zone. Extracapsular extension was seen in 14 cases. Tumor Gleason score was 8 or above in 12 of 15 cases, and ductal type adenocarcinoma was identified in 4. Step section histopathological correlation (n = 5) demonstrated that the pseudocapsule corresponded with dense compressive or reactive peritumoral fibrosis. A pseudocapsule around prostate cancer at T2-weighted MR imaging is a rare finding that appears to be associated with high grade and stage disease.

Keywords

MR imaging; prostate cancer; pseudocapsule; pathology

1.1 Introduction

MR imaging is increasingly used for localization and staging of prostate cancer [1, 2]. On T2-weighted imaging, prostate cancer is typically seen as focal, non-encapsulated, low signal intensity that has an ellipsoid or crescentic subcapsular shape in the peripheral zone or an infiltrative “erased charcoal” appearance in the central gland. Such foci are especially suspicious when accompanied by additional abnormalities on multiparametric imaging, such as restricted diffusion, early intense enhancement, rapid washout, or a malignant spectral

Address for correspondence. Dr. Fergus Coakley, Professor and Chair, Department of Diagnostic Radiology, Oregon Health & Science University, Mail Code: L340, 3181 SW Sam Jackson Park Road, Portland, OR 97239, Tel: 503.494.2570, Fax: 503.494.4982, coakleyf@ohsu.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

signature [3, 4]. Peripheral zone and central gland cancers typically do not have a tumor capsule, and encapsulation is generally considered indicative of nodules derived from benign prostatic hyperplasia [4]. There is only one case report describing the finding of a pseudocapsule surrounding a prostate cancer [5]. However, we have encountered several cases of prostate cancer accompanied by the finding of a pseudocapsule. Therefore, we undertook this study to report the clinicopathological correlates of prostate cancer associated with a pseudocapsule at T2-weighted MR imaging.

1.2 Materials and methods

1.2.1 Subjects

This was a retrospective study conducted at two institutions and approved by both Institutional Review Boards, with waiver of the requirement for informed consent. The study was compliant with the requirements of the Health Insurance Portability and Accountability Act. Based on the records of our multidisciplinary urology tumor boards and the senior author (---), we retrospectively identified 15 patients with prostate cancer associated with a pseudocapsule at T2-weighted MR imaging seen at two institutions between 2000 and 2015. In all cases, the diagnosis of prostate cancer was established by transrectal ultrasound guided biopsy. All available clinical, imaging, and histopathological records were reviewed by the principal investigator (---), with attention to demographics, clinical presentation, imaging findings, histopathological results, management, and outcome. In patients who proceeded to radical prostatectomy at our institutions, we reviewed the histopathological correlate of the pseudocapsule in conjunction with two attending genitourinary pathologists (---, ---).

1.2.2 MRI technique

The detailed scan protocols used at the two institutions are shown in Table 1. At institution A, studies were performed on a 3T whole body MRI scanner (Ingenia; Philips Healthcare, Netherlands). At institution B, studies were performed on 3T scanner (General Electric Healthcare Technologies, Waukesha, WI). At both institutions, a body coil was used for excitation and an inflatable endorectal coil (Medrad; Pittsburgh, PA) in conjunction with a pelvic phase array coil was used for signal reception.

1.2.3 MRI interpretation

All MR images of the 15 retrospectively identified patients with a pseudocapsule cancer were reviewed by two attending radiologists (---, ---) on a picture archiving and communication system workstation (Impax; Agfa, Mortsel, Belgium) and, by consensus, the two readers identified dominant tumor site and size, presence of tumor pseudocapsule, and staging findings. Tumor size was measured as the maximum axial diameter. Using an amalgam of previously described methodologies [3, 6, 7], prostate cancer was defined as focal low T2 signal intensity with an ellipsoid or crescentic subcapsular morphology in the peripheral zone or infiltrative “erased charcoal” non-encapsulated appearance in the central gland accompanied by focal reduction in apparent diffusion coefficient or accompanied by focal early intense enhancement or rapid washout at perfusion imaging. A pseudocapsule was defined as a visible rim of low T2 signal intensity around all or part of the tumor margin that was not abutting the true capsule of the prostate gland or the pseudocapsule of the

central gland. The radial distance of extracapsular extension, if present, was measured, using a previously described methodology [8].

1.3 Results

The clinical, pathological, and radiological findings in the study population are summarized in Table 2. Mean patient age was 67 years (range, 52 to 87). Mean baseline serum prostate specific antigen level was 26.2 ng/mL (range, 0.2 to 76). Mean tumor diameter at MR imaging was 3.4 cm (range, 1.0 to 7.2). Fourteen of 15 tumors involved the peripheral zone. MR findings of extracapsular extension, seminal vesicle invasion, pelvic adenopathy, and pelvic bone metastases were seen in 14, 7, 2 and 2 cases, respectively. The mean radial distance of extracapsular extension was 11 mm (range, 1 to 24). Eleven of 14 patients had extracapsular extension over 5 mm. Tumor Gleason score was 8 or above in 12 of 15 cases, and ductal type adenocarcinoma was identified in 4 of 15. Patients with known treatment (n = 11) were managed primarily by radical prostatectomy (n = 6), radiation (n = 3), or androgen deprivation therapy alone (n = 2). After a median follow up of 18 months (range, 3 to 44) in these 11 patients, 6 are alive with disease, 4 are in remission, and one has died of progressive disease. Step section histopathological correlation in the patients who underwent radical prostatectomy at our institutions (n = 5) demonstrated that the pseudocapsule corresponded with dense compressive or reactive peritumoral fibrosis (Figures 1 and 2).

1.4 Discussion

This study describes a series of patients with prostate cancer that demonstrated a pseudocapsule at T2-weighted MR imaging. Our results suggest this represents dense compressive or reactive peritumoral fibrosis around the tumor, and that this finding is associated with high grade and stage disease. These observations have a number of practical implications. First, a pseudocapsule of low T2 signal in the prostate is generally considered a feature of benign prostate hyperplasia, and absence of a capsule is generally considered a feature of prostate cancer [4]. Our study adds a note of caution to this approach. For prostate lesions with a pseudocapsule that are large, in the peripheral zone, or appear associated with extension beyond the prostate capsule or seminal vesicle invasion, malignancy should be included in the differential. However, review of the cases in our study suggests that experienced readers of prostate MR imaging should have little difficulty in distinguishing a pseudocapsule prostate cancers from benign prostate hyperplasia; most of the tumors in this study were in the peripheral zone or associated with locally advanced disease. Second, recognition that a pseudocapsule around prostate cancer at T2-weighted MR imaging portends an aggressive tumor of high grade may be of clinical utility, highlighting the need for more intensive treatment, such as extended androgen deprivation therapy. This could be useful in cases where standard systematic biopsy under-graded the primary tumor, a well-recognized phenomenon [8]. In such a scenario, radiology could play a key role in guiding management. Our finding that 11 of 15 patients had extracapsular extension exceeding 5 mm in radial distance further reinforces the prognostic importance of tumor encapsulation. In a study of patients evaluated by MRI prior to radiation therapy, extracapsular extension greater than 5 mm in radial distance was associated with early metastatic recurrence in 3 of 5

patients [8]. Of course, tumor encapsulation may not be an independent negative prognostic factor, but recognizing the association with worse prognosis could still be clinically helpful.

To our knowledge, only one prior report has described a pseudocapsule around prostate cancer at MR imaging, in which a 72 year old man was found to have a surgically confirmed Gleason score 3+4 cancer extending exophytically from the prostate with a T2 hypointense rim or capsule [5]. This is in accordance with the finding that all 15 patients in our series had high or intermediate grade Gleason scores. Interestingly, the implication that a pseudocapsule of prostate cancer is associated with high grade disease and presumably a poorer prognosis contrasts with the published literature on radiologically identified pseudocapsule around other malignancies. For example, a pseudocapsule around renal cell carcinoma and hepatocellular carcinoma appears to be associated with a more favorable prognosis [10-14].

Our study has several limitations. This was a retrospective study with a small sample size. As the patients were identified based on the records of tumor boards and the senior author, it is possible that there may have been selection bias in case identification. Specifically, nodules with a pseudocapsule at MR imaging may be more likely to be diagnosed as malignant if they are large, advanced, or in the peripheral zone, and so our study might have been skewed towards inclusion of such cases. However, if smaller nodules with a pseudocapsule in the central gland were malignant with any frequency, it seems likely that this would be a recognized clinical phenomenon, given that such cases would presumably return for re-imaging due to progressive rises in prostatic specific antigen. We are unaware of any studies describing such observations. Because the cases were collected over a long time period from two institutions, patients were not studied with a standard multiparametric protocol incorporating diffusion and perfusion imaging. As a result, we do not know how diffusion and perfusion findings might help in the distinction of encapsulated prostate cancer from encapsulated nodules of benign prostatic hyperplasia. Larger and more comprehensive studies will be required to address these limitations, incorporating contemporary multiparametric MR sequences across all patients, comparison with benign encapsulated nodules, and systematic comparative analyses. The lack of histopathological correlation in many cases is a further limitation, but reflects the advanced nature of these tumors, such that many patients were managed without surgery.

1.5 Conclusions


In conclusion, the finding of a pseudocapsule around prostate cancer at T2-weighted MR imaging is a rare finding that corresponds with compressive or reactive peritumoral fibrosis at histopathology and appears to be associated with high grade and stage disease.

Acknowledgments


DP supported by NIH grant 1R25EB016671

1.6 References


1. Yacoub JH, Oto A, Miller FH. MR imaging of the prostate. *Radiol Clin North Am.* 2014; 52:811–37. [PubMed: 24889173]
2. Porten SP, Smith A, Odisho AY, et al. Updated trends in imaging use in men diagnosed with prostate cancer. *Prostate Cancer Prostatic Dis.* 2014; 17:246–51. [PubMed: 24819235]
3. Jung AJ, Westphalen AC, Kurhanewicz J, et al. Clinical utility of endorectal MRI-guided prostate biopsy: preliminary experience. *J Magn Reson Imaging.* 2014; 40:314–23. [PubMed: 24924999]
4. PIRADS. [accessed February 6, 2015] <http://www.acr.org/~media/ACR/Documents/PDF/QualitySafety/Resources/PIRADS/PIRADS%20V2.pdf>
5. Satoa Y, Oguroa T, Kumagaia S, et al. Prostatic adenocarcinoma with pseudocapsule. *World J Nephrol Urol.* 2013; 2:18–20.
6. Siddiqui MM, Rais-Bahrami S, Truong H, et al. Magnetic Resonance Imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. *Eur Urol.* 2013; 64:713–719. [PubMed: 23787357]
7. Pokorny MR, de Rooij M, Duncan E, et al. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. *Eur Urol.* 2014; 66:22–9. [PubMed: 24666839]
8. McKenna DA, Coakley FV, Westphalen AC, et al. Prostate cancer: role of pretreatment MR in predicting outcome after external-beam radiation therapy--initial experience. *Radiology.* 2008; 247:141–6. [PubMed: 18258811]
9. Grossfeld GD, Chang JJ, Broering JM, et al. Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: results from the Cancer of the Prostate Strategic Urologic Research Endeavor database. *J Urol.* 2001; 165:851–6. [PubMed: 11176485]
10. Lu DS, Siripongsakun S, Kyong Lee J, et al. Complete tumor encapsulation on magnetic resonance imaging: a potentially useful imaging biomarker for better survival in solitary large hepatocellular carcinoma. *Liver Transpl.* 2013; 19:283–91. [PubMed: 23280814]
11. Chu KK, Chan SC, Fan ST, et al. Radiological prognosticators of hepatocellular carcinoma treated by hepatectomy. *Hepatobiliary Pancreat Dis Int.* 2012; 11:612–7. [PubMed: 23232632]
12. Ishigami K, Yoshimitsu K, Nishihara Y, et al. Hepatocellular carcinoma with a pseudocapsule on gadolinium-enhanced MR images: correlation with histopathologic findings. *Radiology.* 2009; 250:435–43. [PubMed: 19095782]
13. Roy C Sr, El Ghali S, Buy X, et al. Significance of the pseudocapsule on MRI of renal neoplasms and its potential application for local staging: a retrospective study. *AJR Am J Roentgenol.* 2005; 184:113–20. [PubMed: 15615960]
14. Yamashita Y, Honda S, Nishiharu T, et al. Detection of pseudocapsule of renal cell carcinoma with MR imaging and CT. *AJR Am J Roentgenol.* 1996; 166:1151–5. [PubMed: 8615260]



a



b



c

Figure 1.


a:- Axial T2-weighted MR image in a 69 year old man with a serum PSA of 29.9 ng/ml and Gleason score 5+4 prostate cancer in 13 of 13 cores on systematic biopsy (patient #1 in Table 1) showing a large mass (arrow) arising from the left side of the prostate with extensive extracapsular extension. The mass is surrounded by a thin rim of low T2 signal intensity, which also interdigitates within the mass, resulting in a vermiform appearance.

b:- Coronal T2-weighted MR image shows the tumor mass (T) distinct from the left seminal vesicle (arrow), indicating the vermiform appearance in Figure 1a does not represent seminal vesicle invasion.

c:- Photomicrograph of a hematoxylin and eosin-stained slide of the extracapsular tumor mass shows a nodule of prostate cancer (C) surrounded by a thick band of stromal desmoplastic fibrosis (between arrows). The cancer demonstrates involution as a consequence of pre-operative androgen deprivation therapy.



a



b

Figure 2.

a:- Axial T2-weighted MR image in a 60 year old man with a serum PSA of 9.5 ng/ml and Gleason score 5+4 prostate cancer in 5 of 12 cores on systematic biopsy (patient #13 in Table 1) showing a circular nodule (arrow) of low T2 signal intensity in the peripheral zone of the right base surrounded by a thin rim of low T2 signal intensity.

b:- Photomicrograph of a hematoxylin and eosin-stained slide of the tumormargin shows an expansile nodule of high grade prostate cancer (asterisk) surrounded by a thick band of

fibrosis (between arrows) that appears to represent compressed adjacent prostatic parenchyma.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 1
 Details of the diagnostic endorectal multiparametric MRI protocols used at the two institutions in the study.

Parameter	T1	T2
Sequence	Axial fast spin echo	Axial & coronal fast spin echo
Anatomic coverage	Pelvis	Prostate
TR/TE (msec/msec)	400-600/10	Minimum/120
Echo train length	4	26
PI acceleration factor	1.6	1.3
Matrix	352 × 352	560 × 560
Field of view (cm)	30	18
Number of excitations	2	3
Slice thickness/gap (mm)	5/0.5	3/0
Specific to sequence	Transverse frequency direction	Anteroposterior frequency direction for axials
Fat suppression	NA	NA
Sequence	Axial 3D spoiled gradient echo	Oblique axial & coronal fast spin echo
Anatomic coverage	Pelvis	Prostate
TR/TE (msec/msec)	In Phase	6000/102
Echo train length	NA	16
PI acceleration factor	NA	NA
Matrix	192 × 128	384 × 384
Field of view (cm)	24	18 (Coronal = 14)
Number of excitations	2	2
Slice thickness/gap (mm)	4.2/2	3/0
Specific to sequence	Frequency direction A/P	Frequency direction A/P Coronal: Frequency direction S/I
Fat suppression	NA	NA

Table 2

Clinical and imaging characteristics of the 15 patients in the study group with pseudoencapsulated prostate cancer at T2-weighted MRI.

	Age	Baseline serum PSA* (ng/mL)	Baseline clinical stage	Gleason score	Dominant tumor location	Size (cm)	Radial diameter of extracapsular extension (mm)	Seminal vesicle invasion	Enlarged nodes	Bone metastasis	Follow up (month)	Treatment and outcome
1	69	29.9	T3	G5+4 (ductal)	Left peripheral zone	4.6	24	No	No	No	6	Androgen deprivation therapy prior to prostatectomy; PSA currently undetectable.
2	66	37.0	T1	G4+4 (ductal)	Left peripheral zone	4.0	20	Yes	No	No	N/A	Lost to follow-up.
3	58	34.0	Unknown	G4+4	Right peripheral zone	3.0	12	No	No	Yes	42	Androgen deprivation therapy prior to prostatectomy. Radiation to single bone metastasis. Stable PSA < 0.5.
4	58	2.2	T2	4+3	Left apical peripheral zone	1.0	4	No	No	No	35	Prostatectomy. PSA remains undetectable.
5	52	28.0	Unknown	4+4 (ductal)	Left peripheral zone	2.0	1	No	Yes	No	N/A	Lost to follow-up.
6	72	70.0	T1	4+4	Predominantly exophytic and superior to the bladder	6.9	12	Yes	No	No	N/A	Lost to follow-up.
7	57	0.2 ^{***}	T2	4+4	Entire gland involved	4.6	24	Yes	No	No	44	Androgen deprivation therapy and radiation. Alive without recent PSA assay.
8	60	3.9	T2	4+3	Right peripheral zone and central gland	3.5	10	No	No	No	5	Prostatectomy. Biochemical recurrence with current PSA of 6.5.
9	81	9.9	T1	4+4 (ductal)	Left peripheral zone	3.3	12	No	No	No	26	Androgen deprivation therapy and radiation. Current PSA < 0.1.
10	87	76.0	T3	4+5	Left peripheral zone	4.9	13	Yes	No	No	12	Androgen deprivation therapy. Current PSA < 0.5 and stable.
11	79	6.2	Unknown	5+5	Bilateral peripheral zone	7.2	10	Yes	No	No	N/A	Lost to follow-up.
12	61	46.0	Unknown	3+4	Left peripheral zone	2.6	6	Yes	Yes	Yes	16	Androgen deprivation therapy. Died of disease 16 months after diagnosis.
13	60	6.9	T1	5+4	Right-base peripheral zone	1.1	6	Yes	No	No	3	Prostatectomy.

	Age	Baseline serum PSA* (ng/mL)	Baseline clinical stage	Gleason score	Dominant tumor location	Size (cm)	Radial diameter of extracapsular extension (mm)	Seminal vesicle invasion	Enlarged nodes	Bone metastasis	Follow up (month)	Treatment and outcome
14	65	33	T1	3+4	Right-apex central gland	1.6	0	No	No	No	4	Prostatectomy.
15	78	9.7	T2	4+4	Left mid gland peripheral zone	1.4	2	No	No	No	4	Radiation and adjuvant androgen deprivation therapy, with falling PSA.

* Prostatic specific antigen.

** Tumor was poorly differentiated at pathological examination, likely explaining low PSA level.